Syngene, established in 1993 as a subsidiary of Biocon, holds the distinction of being India’s pioneering Contract Research Organization (CRO). Over the years, the company has grown into a comprehensive integrated service provider, offering a seamless platform encompassing drug discovery, development, and manufacturing services – known as CRAMS.
Boasting an extensive research and manufacturing infrastructure, spanning an impressive 1.9 million square feet across multiple locations, Syngene remains at the forefront of the pharmaceutical industry. With a substantial market cap of ₹ 29,460 Cr as of November 18, 2023, the company continues to spearhead innovation and advancement in the field of life sciences
With its strong market presence, diverse service offerings, and impressive infrastructure, Syngene presents an exciting opportunity for investors looking to capitalize on the dynamic growth potential within the pharmaceutical sector.
HOW TO PURCHASE SYNGENE INTERNATIONAL SHARE?
Below are the trading platforms that you can use to purchase Syngene International shares:
- Zerodha
- Upstox
- Groww
- AngelOne
- ICICIDirect
- Paytm Money (Recommended)
SYNGENE INTERNATIONAL IN RECENT NEWS
- Syngene International Limited has recently disclosed its acquisition of the Unit 3 Biologics Manufacturing Facility in Bangalore, India, from Stelis Biopharma Limited.
- Syngene International’s net profit has increased by 26% in Q1FY24, with a remarkable surge of 25.4% in revenue.
Syngene Q2 FY2024 Earnings Report: Summary
Syngene International Limited reported strong financial results for the second quarter and first half of the fiscal year 2024.
Key highlights include:
Second Quarter Results:
- Revenue from operations increased by 18.5% year-on-year to Rs. 910 crores.
- Profit after tax (before exceptional items) rose by 20% to Rs 122 crores.
- At constant currency, the revenue growth was around 15%.
First Half Results:
- Revenue from operations for the first half increased by 22% to Rs 1,718 crores.
- Profit after tax (before exceptional items) grew by 23% to Rs 215 crores.
- The revenue growth at constant currency for the first half was around 17%.
Operational Highlights:
- The company saw strong performances in Development and Manufacturing Services.
- Syngene added a new non-GMP capability center and commissioned a digitally-enabled Quality Control laboratory for biologics.
- Progress was made on a biologics partnership with Zoetis and the acquisition of a multi-modal facility from Stelis Biopharma Ltd.
Market Dynamics:
- While global demand for Discovery Services remained healthy, the US-based biotech segment showed signs of slowed growth.
- The company expects continued growth but at a lower level in the second half of the year due to the temporary slowdown in US biotech funding.
Company Outlook:
- Adjustments to previous guidance were made, with revenue now expected to grow in the mid-teens on a constant currency basis.
- Syngene plans to invest in new science, technology, and digitization while maintaining margins.
Syngene, serving various sectors like pharmaceuticals, biotechnology, and consumer goods, highlighted its commitment to innovation and growth amidst changing market conditions.
SYNGENE INTERNATIONAL SHARE PRICE TARGET: 2023 – 2030
SYNGENE INTERNATIONAL SHARE PRICE TARGET 2023
| When | Maximum Price | Minimum Price |
| November 2023 | ₹774.74 | ₹675.22 |
| December 2023 | ₹778.32 | ₹678.47 |
Based on the projected share price targets for Syngene International Limited in 2023, the stock is expected to demonstrate a positive trend throughout the year. In November 2023, the share price is anticipated to fluctuate between ₹774.74 and ₹675.22.
In the last quarter, Syngene International accomplished three significant milestones. Firstly, they successfully acquired a biologics manufacturing facility in Bangalore from Stelis Biopharma Ltd, as previously announced.
Secondly, the company received regulatory approval from the US Food and Drug Administration for its commercial manufacturing plant in Mangalore. Lastly, Syngene International expanded its operations by acquiring additional land in Hyderabad, which will support its future growth initiatives.
As of 18th November 2023, Syngene International is trading at Rs. 734.
SYNGENE INTERNATIONAL SHARE PRICE TARGET 2024
| When | Maximum Price | Minimum Price |
| January 2024 | ₹824.55 | ₹703.95 |
| February 2024 | ₹853.14 | ₹728.82 |
| March 2024 | ₹862.77 | ₹737.19 |
| April 2024 | ₹875.24 | ₹761.08 |
| May 2024 | ₹821.82 | ₹714.63 |
| June 2024 | ₹886.19 | ₹757.56 |
| July 2024 | ₹936.88 | ₹814.68 |
| August 2024 | ₹1,030.57 | ₹896.15 |
| September 2024 | ₹1,082.10 | ₹940.95 |
| October 2024 | ₹1,040.48 | ₹904.76 |
| November 2024 | ₹1,050.88 | ₹913.81 |
| December 2024 | ₹1,061.39 | ₹922.95 |
Based on the projected share price targets for Syngene International Limited in 2024, the stock is expected to continue its positive trajectory, offering potential opportunities for investors. Starting in January, the share price is anticipated to range between ₹703.95 and ₹824.55. As we move through the year, February and March indicate further growth with the share price reaching highs of ₹853.14 and ₹862.77, respectively, and minimum prices of ₹728.82 and ₹737.19.
In April 2024, Syngene International’s share price is expected to keep growing and hit a maximum of ₹875.24. May 2024 could be a bearish month. The bull run however is expected to continue till December 2024, when we are expecting Syngene International to reach a maximum of Rs. 1,061.39.
For the first time ever, Syngene is expected to reach Rs. 1000 for the first time in the month of August 2024.
SYNGENE INTERNATIONAL SHARE PRICE TARGET 2025
| When | Maximum Price | Minimum Price |
| January 2025 | ₹1,082.62 | ₹832.78 |
| February 2025 | ₹1,139.60 | ₹876.61 |
| March 2025 | ₹1,196.58 | ₹920.45 |
| April 2025 | ₹1,068.37 | ₹821.83 |
| May 2025 | ₹971.25 | ₹747.11 |
| June 2025 | ₹1,068.37 | ₹821.83 |
| July 2025 | ₹1,017.50 | ₹782.69 |
| August 2025 | ₹1,059.89 | ₹815.30 |
| September 2025 | ₹1,112.89 | ₹856.07 |
| October 2025 | ₹1,179.66 | ₹907.43 |
| November 2025 | ₹1,203.26 | ₹925.58 |
| December 2025 | ₹1,227.32 | ₹944.09 |
The share price targets for Syngene International in 2025 present an optimistic outlook for potential investors.
Starting the year in January, the share price is expected to fluctuate between ₹832.78 and ₹1,082.62. As we move through the months, February and March indicate a further increase in value, reaching highs of ₹1,139.60 and ₹1,196.58, with corresponding lows of ₹876.61 and ₹920.45.
April and May may witness some fluctuations, with prices ranging between ₹821.83 to ₹1,068.37 and ₹747.11 to ₹971.25, respectively. The trend remains positive in June, with a potential share price range of ₹821.83 to ₹1,068.37.
Overall, 2025 shows potential for Syngene International’s stock to experience growth, making it an attractive option for investors seeking potential returns in the pharmaceutical sector.
SYNGENE INTERNATIONAL SHARE PRICE TARGET: 2026 – 2030
| Year | Maximum Price | Minimum Price |
| 2026 | ₹1,288.69 | ₹902.08 |
| 2027 | ₹1,417.56 | ₹992.29 |
| 2028 | ₹1,984.58 | ₹992.29 |
| 2029 | ₹1,718.25 | ₹859.13 |
| 2030 | ₹2,233.73 | ₹1,563.61 |
The share price projections for Syngene International Limited from 2026 to 2030 show a promising and upward trajectory, making it an enticing prospect for potential investors. Starting in 2026, the share price is expected to fluctuate between ₹902.08 and ₹1,288.69. Moving into 2027, the prices are projected to rise further, with highs of ₹1,417.56 and lows of ₹992.29.
The year 2028 presents a significant growth potential, as the share price is estimated to reach as high as ₹1,984.58, with a minimum of ₹992.29. While 2029 may experience some fluctuations, with prices ranging from ₹859.13 to ₹1,718.25, 2030 promises substantial growth, with a projected range of ₹1,563.61 to ₹2,233.73. These predictions highlight Syngene’s potential for impressive returns over the next few years, making it an attractive long-term investment option.
SYNGENE INTERNATIONAL FINANCIAL CONDITION: LAST 5 YEARS
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Sales (in Crore INR) |
1,826 | 2,012 | 2,184 | 2,604 | 3,193 |
| Expenses (in Crore INR) |
1,289 | 1,394 | 1,507 | 1,861 | 2,251 |
| Operating Profit (in Crore INR) |
537 | 618 | 678 | 743 | 942 |
| OPM % | 29% | 31% | 31% | 29% | 30% |
| Other Income (in Crore INR) |
75 | 153 | 94 | 75 | 63 |
| Interest (in Crore INR) |
32 | 35 | 28 | 24 | 45 |
| Depreciation (in Crore INR) |
164 | 219 | 274 | 310 | 366 |
| Profit before tax (in Crore INR) |
415 | 517 | 469 | 484 | 594 |
| Tax % | 20% | 20% | 14% | 18% | 22% |
| Net Profit (in Crore INR) |
332 | 412 | 405 | 396 | 464 |
| EPS in Rs | 8.29 | 10.30 | 10.12 | 9.88 | 11.57 |
| Dividend Payout % | 3% | 0% | 0% | 10% | 11% |
Over the last five years, Syngene International has exhibited a commendable financial performance, reflecting its steady growth and resilience in the pharmaceutical industry. With consistent revenue increases, sales have surged from 1,826 in 2019 to an impressive 3,193 in 2023. Despite rising expenses, the company has efficiently managed its operations, maintaining a healthy operating profit margin ranging from 29% to 31%.
Moreover, the company’s prudent financial management is evident in its ability to generate additional income from various sources. Notably, Syngene’s net profit has steadily risen, reaching 464 in 2023, showcasing its robust financial condition and potential for further growth. The company’s commitment to shareholders is evident through its gradual increase in the dividend payout percentage, making it an appealing prospect for investors seeking long-term stability and consistent returns.
GAURAV BISSA ON SYNGENE INTERNATIONAL SHARE PRICE
Gaurav Bissa, a representative from InCred Equities, recommends purchasing Syngene International, with a target price of Rs 825.
FAQS
WHAT IS THE CURRENT SHARE PRICE OF SYNGENE INTERNATIONAL?
As of November 18th, 2023, Syngene International’s share price stands at INR 734.
Taking into account the present market trends and thorough market analysis, the projected share price range for Syngene International in 2024 is estimated to be between ₹714.63 (minimum) and ₹1,082.10 (maximum).
After careful evaluation of current market trends and in-depth market analysis, the projected share price range for Syngene International in 2025 is expected to span from a minimum of ₹500.09 to a maximum of ₹650.12.
Based on our price prediction, it is unlikely that Syngene International’s share price will reach 5000 INR by the end of 2025.
WHAT ARE THE FACTORS THAT CAN IMPACT SYNGENE INTERNATIONAL
The future share price of Syngene International can be influenced by various factors such as economic conditions, interest rates, competition, regulatory changes, and the company’s performance. Investors should closely monitor these factors and adapt their investment strategies accordingly.
ALSO READ
Conclusion: Is Syngene International a Good stock to buy in 2023?
Syngene International Limited, India’s pioneering Contract Research Organization (CRO) and a subsidiary of Biocon, presents a compelling investment opportunity for those seeking to capitalize on the dynamic growth potential within the pharmaceutical sector. With a strong track record of consistent revenue and profit growth over the years, Syngene’s expanding portfolio of end-to-end drug discovery, development, and manufacturing services positions it for continued success.
After the successful last quarter result, the Chief Financial Officer of Syngene International, Sibaji Biswas, affirmed that the company’s financial performance is in line with their projected revenue growth for the year, considering constant currency fluctuations. Despite investing in the expansion of their biologics manufacturing and discovery services portfolios, the company remains committed to maintaining a robust balance sheet and keeping a low debt profile.
The positive share price projections from 2023 to 2030 further reinforce its potential for substantial returns. Backed by expert recommendations and a target price of Rs 825, investors are encouraged to consider Syngene as a valuable addition to their portfolio, contributing to groundbreaking advancements in the world of healthcare and life sciences.
Disclaimer: We have holdings in Syngene. We are not a SEBI registered financial advisor. This is not a financial advise. The article ‘SYNGENE SHARE PRICE TARGET 2023 to 2030’ is only for educational purpose.
What did we learn?
- 1 HOW TO PURCHASE SYNGENE INTERNATIONAL SHARE?
- 2 SYNGENE INTERNATIONAL IN RECENT NEWS
- 3 Syngene Q2 FY2024 Earnings Report: Summary
- 4 SYNGENE INTERNATIONAL SHARE PRICE TARGET: 2023 – 2030
- 5 SYNGENE INTERNATIONAL FINANCIAL CONDITION: LAST 5 YEARS
- 6 GAURAV BISSA ON SYNGENE INTERNATIONAL SHARE PRICE
- 7 FAQS
- 7.1 WHAT IS THE CURRENT SHARE PRICE OF SYNGENE INTERNATIONAL?
- 7.2 WHAT IS THE EXPECTED SHARE PRICE TARGET OF SYNGENE INTERNATIONAL FOR THE YEAR 2024?
- 7.3 WHAT IS THE EXPECTED SHARE PRICE TARGET OF SYNGENE INTERNATIONAL FOR THE YEAR 2025?
- 7.4 CAN SYNGENE INTERNATIONAL’S SHARE PRICE REACH 5000 INR BY 2025?
- 7.5 WHAT ARE THE FACTORS THAT CAN IMPACT SYNGENE INTERNATIONAL’S SHARE PRICE IN THE FUTURE?
- 8 Conclusion: Is Syngene International a Good stock to buy in 2023?
